Suzanne Strickland
Neurology with Special Qualifications in Child Neurology · Augusta, GANPI 1104040690
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,386 of the $7,564 with a category attached, or 84.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,407 and has fallen 70.3% since, to $715 in 2025.
Across 315 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- UCB, Inc.$947
- Sunovion Pharmaceuticals Inc.$632
- Neurelis, Inc.$575
- Supernus Pharmaceuticals, Inc.$520
- Greenwich Biosciences, Inc.$503
- plus $3K from 25 others
What the payments were for
- Travel & lodging$1,17316%
- Food & beverage$6,38684%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,647 |
| UCB, Inc. | 41 | $947 |
| Sunovion Pharmaceuticals Inc. | 58 | $632 |
| Neurelis, Inc. | 26 | $575 |
| Supernus Pharmaceuticals, Inc. | 42 | $520 |
| Greenwich Biosciences, Inc. | 29 | $503 |
| Jazz Pharmaceuticals Inc. | 15 | $447 |
| SK Life Science, Inc. | 17 | $422 |
| Eisai Inc. | 12 | $381 |
| Catalyst Pharmaceuticals, Inc. | 14 | $280 |
| AstraZeneca | 4 | $219 |
| Harmony Biosciences LLC | 9 | $217 |
| Aquestive Therapeutics, Inc. | 7 | $142 |
| Novartis | 6 | $112 |
| Zogenix Inc. | 5 | $81 |
| Biogen | 3 | $66 |
| Sarepta Therapeutics, Inc. | 2 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $41 |
| Neos Therapeutics, LP | 2 | $32 |
| Otter Pharmaceuticals, LLC | 1 | $32 |
| Genentech USA, Inc. | 1 | $27 |
| Grifols USA, LLC | 2 | $26 |
| Immedica Pharma US, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| ITF Therapeutics LLC | 1 | $21 |
| Aprecia Pharmaceuticals, LLC | 1 | $21 |
| Amgen | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,598
- Epidiolex$273
- Fycompa$224
- Banzel$104
How this compares
$7,564 in reported general payments places this provider in the 70th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnfiClobazam | 13 | $34,704 |
| Phenobarbital | 14 | $291 |
| Levetiracetam | 14 | $96 |
| Lorazepam | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Augusta
- Yong ParkAugusta$78K
- Elizabeth SekulAugusta$8K
- Marleny Aquino CabreraAugusta$5K
- Abdelrahim AbdelAugusta$1K
- Amanda AndrewsAugusta$1K
- James CarrollAugusta$22
- Bernard MariaAugusta$17
- John HemphillSavannah$2M
- Chaouki KhouryAtlanta$978K
- Katherine MoretzSavannah$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.